drugset / Trial / NCT01477021

Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

NCT01477021 ↗

NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and how well giving autologous T cells with cyclophosphamide works in treating patients with soft tissue sarcoma that is metastatic or cannot be removed by surgery. Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving autologous T cells together with cyclophosphamide may kill more tumor cells.

Timeline

Start
2012-01
Primary completion
2013-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject NY-ESO-1-specific T cells Cell therapy — Intravenous
Background Cyclophosphamide Other / unclassified — Intravenous